Akili Interactive’s $160 Million Equity and Debt Financing

Goodwin Procter LLP advised Akili Interactive on the deal.

Akili Interactive announced its $160 million in combined equity and debt financing.

Akili is the maker of EndeavorRx™, the first-and-only FDA-cleared treatment delivered through a video game experience. Indicated to improve attention function in children with ADHD, EndeavorRx is built on the Akili Selective Stimulus Management Engine (SSME™) core technology, a proprietary technology designed to target key attentional control systems in the brain.

This funding will support a go-to market approach that brings EndeavorRx to families and healthcare professionals at scale and expand Akili’s global footprint within attention-deficit/hyperactivity disorder (ADHD) and beyond. The financing will also enable Akili to build on the success of its patented technology platform, which has shown positive results in clinical trials across a number of indications, and further advance its pipeline of prescription digital therapeutics targeting a range of chronic and acute cognitive disorders.

The Goodwin team for the financing was led by Art McGivern (Picture) and included Mark Smith, Joseph Flynn, and Steven Zhao (Corporate), Jacob Osborn (Global Trade), and Dan Karelitz (Tax), with invaluable assistance from Coleen Doyle.

 

Involved fees earner: Joseph Flynn – Goodwin Procter; Daniel Karelitz – Goodwin Procter; Arthur McGivern – Goodwin Procter; Jacob Osborn – Goodwin Procter; Mark Smith – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Akili Interactive;

Author: Martina Bellini